Targeting the receptor tyrosine kinase, ROS proto-oncogene 1 (ROS1), can lead to synthetic lethality in cancers associated with CDH1 deficiency 7, and several ROS1 inhibitors have been approved to treat non-small cell lung cancers by the US Food and Drug Administration (US FDA) due to their strong clinical responses 8, 9. Here, ROS1 is linked to cancer.